{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:11:35Z","timestamp":1788383495396,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,29]]},"DOI":"10.7759\/cureus.72599","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T07:25:35Z","timestamp":1730186735000},"source":"Crossref","is-referenced-by-count":6,"title":["Recent Developments and Challenges in the Treatment of Acute Leukemia and Myelodysplastic Syndromes: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Nawal","family":"Rafiq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad H","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mashaal","family":"Sahibzada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakeeb Ahmad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aswani","family":"Syamprabha Vijayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najeeb","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenny","family":"Koodarath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar Azam","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falaknaz","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Almounjed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrar","family":"Khaliq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Leukemia","author":"Chennamadhavuni A","year":"2024","unstructured":"Chennamadhavuni A, Lyengar V, Mukkamalla SKR, Shimanovsky A. Leukemia. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092256","article-title":"Etiology of acute leukemia: a review","volume":"13","author":"Tebbi CK","year":"2021","unstructured":"Tebbi CK. Etiology of acute leukemia: a review. Cancers (Basel). 2021, 13:2256. 10.3390\/cancers13092256","journal-title":"Cancers (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel RL","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023, 73:17-48. 10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch JS","year":"2012","unstructured":"Welch JS, Ley TJ, Link DC, et al.. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012, 150:264-78. 10.1016\/j.cell.2012.06.023","journal-title":"Cell"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqaa107","article-title":"Diagnosis and treatment of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC)","volume":"154","author":"Arber DA","year":"2020","unstructured":"Arber DA, Erba HP. Diagnosis and treatment of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC). Am J Clin Pathol. 2020, 154:731-41. 10.1093\/ajcp\/aqaa107","journal-title":"Am J Clin Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.6056","article-title":"Overall survival as the outcome for randomized clinical trials with effective subsequent therapies","volume":"29","author":"Korn EL","year":"2011","unstructured":"Korn EL, Freidlin B, Abrams JS. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol. 2011, 29:2439-42. 10.1200\/JCO.2011.34.6056","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0300637","article-title":"Impact of aging on acute myeloid leukemia epidemiology and survival outcomes: a real-world, population-based longitudinal cohort study","volume":"19","author":"Han HJ","year":"2024","unstructured":"Han HJ, Choi K, Suh HS. Impact of aging on acute myeloid leukemia epidemiology and survival outcomes: a real-world, population-based longitudinal cohort study. PLoS One. 2024, 19:e0300637. 10.1371\/journal.pone.0300637","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.764698","article-title":"The bone marrow microenvironment mechanisms in acute myeloid leukemia","volume":"9","author":"Pimenta DB","year":"2021","unstructured":"Pimenta DB, Varela VA, Datoguia TS, Caraciolo VB, Lopes GH, Pereira WO. The bone marrow microenvironment mechanisms in acute myeloid leukemia. Front Cell Dev Biol. 2021, 9:764698. 10.3389\/fcell.2021.764698","journal-title":"Front Cell Dev Biol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27089","article-title":"Acute myelogenous leukemia in adolescents and young adults","volume":"65","author":"Creutzig U","year":"2018","unstructured":"Creutzig U, Kutny MA, Barr R, Schlenk RF, Ribeiro RC. Acute myelogenous leukemia in adolescents and young adults. Pediatr Blood Cancer. 2018, 65:e27089. 10.1002\/pbc.27089","journal-title":"Pediatr Blood Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7150\/jca.32326","article-title":"The epidemiological trend of acute myeloid leukemia in childhood: a population-based analysis","volume":"10","author":"Chen X","year":"2019","unstructured":"Chen X, Pan J, Wang S, Hong S, Hong S, He S. The epidemiological trend of acute myeloid leukemia in childhood: a population-based analysis. J Cancer. 2019, 10:4824-35. 10.7150\/jca.32326","journal-title":"J Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13769","article-title":"Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: a multicenter international study","volume":"109","author":"Ito T","year":"2022","unstructured":"Ito T, Sanford D, Tomuleasa C, et al.. Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: a multicenter international study. Eur J Haematol. 2022, 109:58-68. 10.1111\/ejh.13769","journal-title":"Eur J Haematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00908-z","article-title":"The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017","volume":"13","author":"Yi M","year":"2020","unstructured":"Yi M, Li A, Zhou L, Chu Q, Song Y, Wu K. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020, 13:72. 10.1186\/s13045-020-00908-z","journal-title":"J Hematol Oncol"},{"key":"ref13","article-title":"Myelodysplastic syndrome","author":"Dotson JL","year":"2024","unstructured":"Dotson JL, Lebowicz Y. Myelodysplastic syndrome. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref14","unstructured":"Myelodysplastic syndromes treatment (PDQ\u00ae)-patient version. (2005). Accessed. September 7, 2024: https:\/\/www.cancer.gov\/types\/myeloproliferative\/patient\/myelodysplastic-treatment-pdq."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000621","article-title":"Structural organization of the bone marrow and its role in hematopoiesis","volume":"28","author":"Lucas D","year":"2021","unstructured":"Lucas D. Structural organization of the bone marrow and its role in hematopoiesis. Curr Opin Hematol. 2021, 28:36-42. 10.1097\/MOH.0000000000000621","journal-title":"Curr Opin Hematol"},{"key":"ref16","unstructured":"Definition & facts for aplastic anemia & myelodysplastic syndromes. (2024). Accessed. September 7, 2024: https:\/\/www.niddk.nih.gov\/health-information\/blood-diseases\/aplastic-anemia-myelodysplastic-syndromes\/definition-facts."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.08.008","article-title":"The classification of MDS: from FAB to WHO and beyond","volume":"36","author":"Vardiman J","year":"2012","unstructured":"Vardiman J. The classification of MDS: from FAB to WHO and beyond. Leuk Res. 2012, 36:1453-8. 10.1016\/j.leukres.2012.08.008","journal-title":"Leuk Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-015-0269-y","article-title":"Incidence and burden of the myelodysplastic syndromes","volume":"10","author":"Cogle CR","year":"2015","unstructured":"Cogle CR. Incidence and burden of the myelodysplastic syndromes. Curr Hematol Malig Rep. 2015, 10:272-81. 10.1007\/s11899-015-0269-y","journal-title":"Curr Hematol Malig Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01409-5","article-title":"The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades","volume":"16","author":"Jabbour E","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, Haddad FG, Welch MA, Ravandi F, Kantarjian H. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol. 2023, 16:22. 10.1186\/s13045-023-01409-5","journal-title":"J Hematol Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.124016","article-title":"Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia","volume":"100","author":"Leoni V","year":"2015","unstructured":"Leoni V, Biondi A. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia. Haematologica. 2015, 100:295-9. 10.3324\/haematol.2015.124016","journal-title":"Haematologica"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00088-1","article-title":"Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372\/COG AALL1122): a single-arm, multicentre, phase 2 trial","volume":"10","author":"Hunger SP","year":"2023","unstructured":"Hunger SP, Tran TH, Saha V, et al.. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372\/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2023, 10:e510-20. 10.1016\/S2352-3026(23)00088-1","journal-title":"Lancet Haematol"},{"key":"ref22","article-title":"Efficacy of bone marrow transplantation in treating acute myeloid leukemia: a systematic review and meta-analysis","volume":"15","author":"Li Y","year":"2023","unstructured":"Li Y, Zhou F. Efficacy of bone marrow transplantation in treating acute myeloid leukemia: a systematic review and meta-analysis. Am J Transl Res. 2023, 15:1-12.","journal-title":"Am J Transl Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian H","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, et al.. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021, 11:41. 10.1038\/s41408-021-00425-3","journal-title":"Blood Cancer J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2217\/ijh-2017-0023","article-title":"Management of older adults with acute lymphoblastic leukemia: challenges & current approaches","volume":"7","author":"Sawalha Y","year":"2018","unstructured":"Sawalha Y, Advani AS. Management of older adults with acute lymphoblastic leukemia: challenges & current approaches. Int J Hematol Oncol. 2018, 7:IJH02. 10.2217\/ijh-2017-0023","journal-title":"Int J Hematol Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte T","year":"2017","unstructured":"de Witte T, Bowen D, Robin M, et al.. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017, 129:1753-62. 10.1182\/blood-2016-06-724500","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.967900","article-title":"Past, present and future in low-risk myelodysplastic syndrome","volume":"9","author":"Toprak SK","year":"2022","unstructured":"Toprak SK. Past, present and future in low-risk myelodysplastic syndrome. Front Med (Lausanne). 2022, 9:967900. 10.3389\/fmed.2022.967900","journal-title":"Front Med (Lausanne)"},{"key":"ref27","unstructured":"CASP checklists. (2024). Accessed. September 7, 2024: https:\/\/casp-uk.net\/casp-tools-checklists\/."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-022-01189-4","article-title":"Modelling acute myeloid leukemia (AML): what's new? A transition from the classical to the modern","volume":"13","author":"Dozzo A","year":"2023","unstructured":"Dozzo A, Galvin A, Shin JW, Scalia S, O'Driscoll CM, Ryan KB. Modelling acute myeloid leukemia (AML): what's new? A transition from the classical to the modern. Drug Deliv Transl Res. 2023, 13:2110-41. 10.1007\/s13346-022-01189-4","journal-title":"Drug Deliv Transl Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_438662","article-title":"Advancements and challenges in the treatment of AML","volume":"44","author":"Abaza Y","year":"2024","unstructured":"Abaza Y, McMahon C, Garcia JS. Advancements and challenges in the treatment of AML. Am Soc Clin Oncol Educ Book. 2024, 44:e438662. 10.1200\/EDBK_438662","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00600","article-title":"Contributions to the American Society of Hematology meeting from low- and middle-income countries: an in-depth analysis and call to action","volume":"7","author":"G\u00f3mez-De Le\u00f3n A","year":"2021","unstructured":"G\u00f3mez-De Le\u00f3n A, Colunga-Pedraza PR, Tar\u00edn-Arzaga L, et al.. Contributions to the American Society of Hematology meeting from low- and middle-income countries: an in-depth analysis and call to action. JCO Glob Oncol. 2021, 7:622-31. 10.1200\/GO.20.00600","journal-title":"JCO Glob Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali RS","year":"2023","unstructured":"Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023, 16:29. 10.1186\/s13045-023-01424-6","journal-title":"J Hematol Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0897","article-title":"Somatic mutations drive specific, but reversible, epigenetic heterogeneity states in AML","volume":"10","author":"Li S","year":"2020","unstructured":"Li S, Chen X, Wang J, et al.. Somatic mutations drive specific, but reversible, epigenetic heterogeneity states in AML. Cancer Discov. 2020, 10:1934-49. 10.1158\/2159-8290.CD-19-0897","journal-title":"Cancer Discov"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49930","article-title":"A review of acute lymphocytic leukemia (ALL) in the pediatric population: evaluating current trends and changes in guidelines in the past decade","volume":"15","author":"Ekpa QL","year":"2023","unstructured":"Ekpa QL, Akahara PC, Anderson AM, et al.. A review of acute lymphocytic leukemia (ALL) in the pediatric population: evaluating current trends and changes in guidelines in the past decade. Cureus. 2023, 15:e49930. 10.7759\/cureus.49930","journal-title":"Cureus"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246246","article-title":"Immunotherapy as a turning point in the treatment of acute myeloid leukemia","volume":"13","author":"Aureli A","year":"2021","unstructured":"Aureli A, Marziani B, Sconocchia T, et al.. Immunotherapy as a turning point in the treatment of acute myeloid leukemia. Cancers (Basel). 2021, 13:6246. 10.3390\/cancers13246246","journal-title":"Cancers (Basel)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1637","article-title":"Myeloablative haploidentical transplantation is superior to chemotherapy for patients with intermediate-risk acute myelogenous leukemia in first complete remission","volume":"25","author":"Lv M","year":"2019","unstructured":"Lv M, Wang Y, Chang YJ, et al.. Myeloablative haploidentical transplantation is superior to chemotherapy for patients with intermediate-risk acute myelogenous leukemia in first complete remission. Clin Cancer Res. 2019, 25:1737-48. 10.1158\/1078-0432.CCR-18-1637","journal-title":"Clin Cancer Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05700-4","article-title":"Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?","volume":"103","author":"Niscola P","year":"2024","unstructured":"Niscola P, Gianfelici V, Giovannini M, Piccioni D, Mazzone C, Fabritiis P. Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?. Ann Hematol. 2024, 103:1787-8. 10.1007\/s00277-024-05700-4","journal-title":"Ann Hematol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01265-7","article-title":"Current challenges and unmet medical needs in myelodysplastic syndromes","volume":"35","author":"Platzbecker U","year":"2021","unstructured":"Platzbecker U, Kubasch AS, Homer-Bouthiette C, Prebet T. Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia. 2021, 35:2182-98. 10.1038\/s41375-021-01265-7","journal-title":"Leukemia"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02001-z","article-title":"Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial","volume":"37","author":"Sekeres MA","year":"2023","unstructured":"Sekeres MA, Montesinos P, Novak J, et al.. Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. Leukemia. 2023, 37:2017-26. 10.1038\/s41375-023-02001-z","journal-title":"Leukemia"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113225","article-title":"Advances in acute myeloid leukemia: recently approved therapies and drugs in development","volume":"12","author":"Stanchina M","year":"2020","unstructured":"Stanchina M, Soong D, Zheng-Lin B, Watts JM, Taylor J. Advances in acute myeloid leukemia: recently approved therapies and drugs in development. Cancers (Basel). 2020, 12:3225. 10.3390\/cancers12113225","journal-title":"Cancers (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/296482-recent-developments-and-challenges-in-the-treatment-of-acute-leukemia-and-myelodysplastic-syndromes-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T07:25:40Z","timestamp":1730186740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/296482-recent-developments-and-challenges-in-the-treatment-of-acute-leukemia-and-myelodysplastic-syndromes-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.72599","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,29]]}}}